Insight Molecular Diagnostics's total assets for Q1 2025 were $60.36M, an increase of 72.06% from the previous quarter. IMDX total liabilities were $50.14M for the fiscal quarter, a 5.89% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.